Table 3 Predictors of shorter brain-specific progression free survival in metastatic breast cancer with leptomeningeal disease.
From: Survival outcomes among patients with breast cancer and leptomeningeal disease
Univariable | Multivariable | |||
|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Older age at initial BC diagnosisa | 1.20 (0.99, 1.45) | 0.0573 | ||
Older age at BrM diagnosisa | 1.23 (1.02, 1.49) | 0.0341 | ||
Older age at LMD diagnosisa | 1.24 (1.03, 1.51) | 0.0268 | ||
LMD diagnosis year (all patients) | ||||
2005-2012 | 1 | |||
2013-2019 | 0.939 (0.62, 1.42) | 0.764 | ||
LMD diagnosis year (HER2+ patients) | ||||
2005-2012 | 1 | |||
2013-2019 | 1.98 (0.75, 5.23) | 0.167 | ||
Time from BrM to LMD (weeks) (continuous) | 1.004 (0.998, 1.01) | 0.159 | 1.01 (1.002, 1.02) | 0.0353 |
Breast cancer subtype | ||||
Triple negative | 1 | |||
HR+HER2- | 0.75 (0.45, 1.26) | 0.2783 | ||
HER2+ | 0.47 (0.25, 0.87) | 0.0156 | ||
HER2+ overexpression | ||||
Negative | 1 | |||
Positive | 0.58 (0.35, 0.95) | 0.0237 | 0.47 (0.25, 0.86) | 0.0102 |
LMD spinal involvement | ||||
Negative | 1 | |||
Positive | 1.37 (0.90, 2.09) | 0.1406 | ||
Karnofsky Performance Scale (KPS) | ||||
60 or higher | 1 | |||
Less than 60 | 3.02 (1.61, 5.69) | 0.0028 | 3.41 (1.71, 6.8) | 0.0013 |
Number of brain metastases | ||||
Single metastasis | 1 | |||
2+ metastases | 1.2 (0.69, 2.09) | 0.5195 | ||
No brain lesion (LMD only) | 1.1 (0.61, 2.02) | 0.7201 | ||
Extracranial metastases (ECM) | ||||
Bone | 0.65 (0.403, 1.058) | 0.0954 | ||
Lung | 0.97 (0.644, 1.471) | 0.8993 | ||
Liver | 1.17 (0.772, 1.775) | 0.4567 | ||
Systemic therapy at LMDb | ||||
Chemotherapy +/- endocrine | 1 | |||
HER2- agent +/- chemotherapy | 0.46 (0.2, 1.05) | 0.0661 | ||
Endocrine therapy alone | 1.11 (0.54, 2.3) | 0.7746 | ||
None | 1.5 (0.88, 2.58) | 0.1387 | ||
